featured
Effects on the Incidence of Cardiovascular Events With the Addition of Pioglitazone vs Sulfonylureas in Type 2 Diabetes Inadequately Controlled With Metformin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effects on the Incidence of Cardiovascular Events of the Addition of Pioglitazone Versus Sulfonylureas in Patients With Type 2 Diabetes Inadequately Controlled With Metformin (TOSCA.IT): A Randomised, Multicentre Trial
Lancet Diabetes Endocrinol 2017 Sep 12;[EPub Ahead of Print], O Vaccaro, M Masulli, A Nicolucci, E Bonora, S Del Prato, AP Maggioni, AA Rivellese, S Squatrito, CB Giorda, G Sesti, P Mocarelli, G Lucisano, M Sacco, S Signorini, F Cappellini, G Perriello, AC Babini, A Lapolla, G Gregori, C Giordano, L Corsi, R Buzzetti, G Clemente, G Di Cianni, R Iannarelli, R Cordera, O La Macchia, C Zamboni, C Scaranna, M Boemi, C Iovine, D Lauro, S Leotta, E Dall'Aglio, E Cannarsa, L Tonutti, G Pugliese, AC Bossi, R Anichini, F Dotta, A Di Benedetto, G Citro, D Antenucci, L Ricci, F Giorgino, C Santini, A Gnasso, S De Cosmo, D Zavaroni, M Vedovato, A Consoli, M Calabrese, P di Bartolo, P Fornengo, G RiccardiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.